Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World August 2009 Derek Lowe	Column: In the pipeline The author considers what makes a good looking drug molecule - and how beauty is in the eye of the beholder
Chemistry World April 2007 Derek Lowe	Opinion: In the Pipeline Natural products can be ridiculously complicated. The sheer difficulty of the enterprise is traditionally what made pharmaceutical companies hire people who had worked in total synthesis. But, is total synthesis research still worth the effort?
Chemistry World December 2008	Column: In the pipeline I've worked on two drug discovery efforts (one right after the other, as fate would have it) whose final compounds differed by essentially one methyl group from the starting points of each project.
Chemistry World October 2010	Column: In the pipeline Derek Lowe investigates the comeback combinatorial chemistry has made in the field of drug discovery
Chemistry World August 2008	Column: In the pipeline Problems develop when there are too few workhorse reactions, which may well generate compounds that are too similar to each other. Are we at that stage now?
Chemistry World August 2007 Derek Lowe	Opinion: In the Pipeline Process chemists just don't get the credit they deserve.
Chemistry World May 20, 2015 Katrina Kramer	Taking the lead on drug discovery Researchers from the UK have developed a straightforward strategy for making compounds that have the potential to become clinical drugs.
Chemistry World June 2008 Sarah Houlton	Breaking the rules The author finds out about some chemical tricks that can give a new drug the best possible odds of success
Chemistry World July 2008 Kevin Rogers	What future for small molecule therapy? Pharmaceutical companies overlook bench chemists at their peril
Chemistry World September 2007 Derek Lowe	Column: In the Pipeline Will Phase Zero trials actually help drug development?
Chemistry World May 31, 2009 Nina Notman	The natural approach to winning at drug discovery High throughput drug screening is often described as a casino, with the odds stacked on the side of success as long as a big enough library is used.
Chemistry World March 2012	Lead-oriented synthesis Ian Churcher and Alan Nadin call for the development of more robust synthetic tools to improve small molecule survival rates in the perilous journey from lead to drug
Chemistry World April 2011	Molecular Obesity is Weighing Down Drug Discovery Medicinal chemistry's quest for potent drug candidates has resulted in molecules that are too large and too lipophilic for their own good.
Chemistry World November 28, 2013	Put the chemistry back in medicinal chemistry Today, synthetic skill is valued and appreciated much less in medicinal chemistry than in chemical development, though it is equally important for both. Much of the blame lies with the mismeasurement of productivity.
The Motley Fool September 20, 2007 Brian Lawler	Discovering Pharmacopeia Pharma investors should watch Pharmacopeia, a tiny drug company with several interesting compounds in development.
Chemistry World September 2008 Derek Lowe	Column: In the pipeline The author remembers leaving the ivory towers of academe to trade 'unusual and beautiful' for 'useful'
Chemistry World October 2008 Derek Lowe	Column: In the pipeline The author seeks a cure for 'compound bloat'
Chemistry World November 2008 Derek Lowe	Column: In the pipeline Drug discovery chemists live by assay data; we depend on these numbers to tell us if we're heading in the right direction with our molecules.
The Motley Fool April 2, 2007 Brian Lawler	A Good Week for Alexza The pharma reports positive clinical trial results. Investors, take note.
The Motley Fool August 31, 2007 Brian Lawler	4 Biotech Bets Under $10 Development stage drugmakers are among the most exciting stocks to follow. Here are four that are all worth a place on your watch list: Pharmacopeia, Pain Therapeutics, Pharmasset, and SGX Pharmaceuticals.
Chemistry World June 2011	Column: In the pipeline Chemists are human. Humans are hierarchical. Therefore...well, therefore, you'll find a number of different roles and levels for scientists in a drug company's labs. Here's a rough ordering, from least experienced to most.
Chemistry World October 2009	Column: In the pipeline Derek Lowe discusses the problem of leaning too heavily on favorite reactions
Chemistry World December 2009	Column: In the pipeline Is the pharmaceutical industry churning out copycat versions of existing therapies? The author dispels a few myths about 'me-too' drugs
Chemistry World January 2012	Column: In the pipeline Derek Lowe discusses how companies are increasingly trying to do more with the compounds they already know a lot about
Chemistry World December 2007 Derek Lowe	Column: In the Pipeline The challenge of biologics.
Chemistry World June 29, 2015	Organic odysseys Valuable compounds often come from the strangest places, and in such small concentrations that synthetic chemistry has to step up.
Pharmaceutical Executive February 1, 2006 Ron Feemster	Gene Logic: Rescue Squad One or two late-stage clinical failures can land promising drug candidates on the shelf. Forever? Maybe not. Gene Logic tests Big Pharma's dead drugs for hundreds of different targets.
Bio-IT World September 2006 Kevin Davies	Pfizer's Global Survey of Pharmacological Space The pharma blends knowledge, computational chemistry and research informatics to build a unified database. Gathering all the data in one place offered greater control for indexing and data retrieval and management, enabling Pfizer scientists to perform global mapping.
The Motley Fool June 29, 2007 Brian Lawler	Genentech's All Good The biotech's latest partnership deal is nothing to worry about. Investors, take note.
Chemistry World March 2011	Column: In the pipeline Drug discovery is an inherently risky business. Derek Lowe tries to balance some of the risk equations
Bio-IT World February 10, 2003 Malorye Branca	Conquering Infinity with Chemical Genetics Harvard superchemist Stuart Schreiber defines the convergence of chemistry and biology. Now the field of chemical genetics is heading toward the clinic.
Bio-IT World April 16, 2004 Kevin Davies	The Matrix Revolutions Serenex, a company dedicated to drug discovery, uses a proprietary matrix, or affinity media, to bind purine-binding protiens - a process that could transform the drug discovery business.
Bio-IT World June 17, 2004 John Garvey	Rational Decisions As companies in the computationally guided rational drug design sector mature, they should be more sure of the boundaries that surround their proprietary technologies.
Chemistry World September 25, 2015 Derek Lowe	Spice up your compounds You and your team are optimizing a lead compound, as medicinal chemists are wont to do -- varying its structure to improve its potency, selectivity and other properties.
Chemistry World June 11, 2008 James Mitchell Crow	New Hope for Anticancer Agent The mode of action of a rare natural product with promising cytotoxic activity has been revealed by scientists in the US while a UK group have come up with a particularly efficient chemical synthesis.
The Motley Fool November 26, 2007 Brian Lawler	Glaxo Goes Holiday Shopping The pharmaceutical giant snaps up another acquisition, privately held Reliant Pharmaceuticals, for $1.65 billion in cash, one of the largest pharma deals of the year.
Chemistry World January 3, 2012 Simon Hadlington	One-pot synthesis creates anticancer candidates Researchers in Germany have developed a simple, rapid and high-yielding cascade synthesis of a collection of polycyclic compounds that resemble indole alkaloid natural products and which interfere with cell division.
Bio-IT World November 12, 2002 James Golden	The Business of Bioinformatics The industry has reached an interesting crossroads. As an academic branch of learning, bioinformatics remains mostly what it always was, a cross-disciplinary endeavor between computer science and molecular biology. But bioinformatics as a money-making proposition has different criteria for success.
Chemistry World June 2010	Column: In the pipeline Derek Lowe looks into his crystal ball to see what the future of medicinal chemistry might be
Chemistry World February 21, 2007 Tom Westgate	Complex Organic Molecules Teamed with Iodine Chemists have developed a method for constructing complex halogen-containing organic molecules from simple compounds in a single step. The discovery could pave the way for the synthesis of many potentially useful naturally occurring molecules.
The Motley Fool September 24, 2007 Brian Lawler	An Array of Good News Small pharmaceutical firm Array BioPharma signs a big partnership deal with Celgene. Investors, take note.
Chemistry World November 2007 Dylan Stiles	Column: Bench Monkey Total synthesis is not immune to the vagaries of fickle fashion.
Chemistry World November 2010	Column: In the Pipeline Should drug companies focus on big markets and the blockbuster dream?
Chemistry World July 10, 2013 Karl Collins	An 'Aye' for details Today, using methods developed by masters of their trade, the modern greats of total synthesis demonstrate that almost any molecule can be prepared given time and effort.
Chemistry World May 2009	Column: In the pipeline Derek Lowe considers what we think we know about how drugs work once we've taken them
Chemistry World November 27, 2013 Derek Lowe	Rolling boulders uphill A lot of preclinical projects don't even get off the ground, and many that do still never deliver anything to the development groups.
Chemistry World June 1, 2012 Derek Lowe	Peace, love and understanding You'd think that the chemists and biologists working in drug discovery would understand each other pretty well by now. You would be wrong about that.
Chemistry World April 2009 Derek Lowe	Column: In the pipeline The author considers the problems of addressing drug development out of sequence
The Motley Fool June 11, 2007 Brian Lawler	Johnson & Johnson's Pretty Pipeline While there are concerns about other parts of Johnson & Johnson (for example, its medical device segment), its pharmaceutical division has a robust pipeline of compounds in development that should pay off in the long haul.
The Motley Fool January 26, 2005 Stephen D. Simpson	The Pipeline to Biotech Success Looking at drug R&D is the best way to begin assessing biotech companies as possible investment opportunities.